Albuquerque, NM, July 8, 2025 – Indica Labs, the global leader in AI-powered digital pathology software and services, today announces that their Pharma Services team is offering quantitative image analysis studies designed and performed to Good Clinical Practice (GCP) standards. With GCP image analysis services, customers can rest assured that the quantitative image analysis data in their translational and clinical studies is of the highest quality and generated according to GCP principles and regulatory guidance.

Indica Labs’ Pharma Services partners with customers to provide AI-powered biomarker analysis, advanced data visualization, and comprehensive image analysis at every stage of R&D, discovery to clinical. The team leverages HALO® image analysis, AI, and image management solutions to help customers get deep, accurate, and timely information from their tissue assays. With experience supporting biomarker studies across a wide range of disease areas, applications, and assay types, GCP image analysis is the latest addition to their industry-leading offerings.

GCP standards are internationally recognized ethical and scientific guidelines that ensure the integrity, reliability, and ethical conduct of clinical trials involving human participants. They encompass principles such as informed consent, data integrity, and regulatory compliance to protect participant rights, safety, and well-being while ensuring the credibility of trial results. In studies featuring digital pathology workflows and image analysis, adherence to GCP standards supports reproducibility, minimizes variability, and facilitates regulatory approval.

Indica Labs’ GCP image analysis services leverage team members’ deep expertise in AI-powered digital pathology and training in regulatory compliance. Members possess years of experience in digital pathology and have completed comprehensive GCP training, ensuring adherence to the standards of clinical research and the highest quality of image analysis data.

To support this standard of excellence, all GCP image analysis at Indica Labs is performed in a regulated, cloud-based GCP environment featuring robust workflows and validated IT systems and software, including Indica Labs’ HALO Link collaborative image management platform. The team also possesses a mature quality management system, with extensive QC processes and QA capabilities ensuring data integrity and adherence to all relevant standards.

“Since 2017, customers from pharma, biotech, and CROs have trusted us to help them solve complex image analysis challenges and meet critical deadlines,” noted Doug Bowman, VP of Indica Labs’ Pharma Services. “Our GCP image analysis service builds on this foundation, enabling us to serve our customers across more studies and at the highest standards of clinical research.”

For more information about Indica Labs’ Pharma Services and how the team can help your organization make fast, informed decisions on its biomarker programs, contact info@indicalab.com.

About Indica Labs: Indica Labs is the global leader in AI-powered digital pathology software and services. Our flagship HALO® and HALO AI platform revolutionizes quantitative evaluation of whole slide images. HALO Link provides collaborative image management while HALO AP® and HALO AP Dx deliver enterprise digital pathology for primary diagnosis with regulatory clearances in multiple markets. Through a commitment to open pathology, performance, scalability, and ease-of-use, we help pharma companies, diagnostic labs, hospitals, research organizations, and Indica’s own Cloud and Pharma Services make discoveries and diagnoses that transform patient care and scientific discovery.

Media Contact:

Eric Runde

erunde@indicalab.com